The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2210-2223

  Papaioannou, Maria ^a   Schleich, Sonja ^b   Prade, Ina ^a   Degen, Stephanie ^a   Roell, Daniela ^a   Schubert, Undine ^a   Tanner, Tamzin ^c   Claessens, Frank ^c   Matusch, Rudolf ^b   Baniahmad, Aria ^a,c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Androgen antagonist; Androgen receptor; Antihormone; Natural compound; Prostate hyperplasia; Pygeum africanum

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ATRARIC ACID; HYDROXYBENZOIC ACID DERIVATIVE; PRIMER DNA;

ARTICLE; CANCER INVASION; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; HYDROXYBENZOIC ACIDS; MALE; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

PRUNUS AFRICANA; PYGEUM;

EID: 72949095664     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00426.x     Document Type: Article

References (53)

1. Sampson N, Untergasser G, Plas E, et al. The ageing male reproductive tract. J Pathol. 2007 211 : 206 218.
2. Skolarikos A, Thorpe AC, Neal DE. Lower urinary tract symptoms and benign prostatic hyperplasia. Minerva Urol Nefrol. 2004 56 : 109 122.
3. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002 38 : 99 166. (Pubitemid 34031832)
4. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004 172 : 1399 1403.
5. Ross R, Bernstein L, Judd H, et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 76 : 45 8.
6. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol. 2003 149 : 469 477.
7. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 60 : 132 138 discussion 138-9.
8. Tenbaum S, Baniahmad A. Nuclear receptors: structure, function and involvement in disease. Int J Biochem Cell Biol. 1997 29 : 1325 1341.
9. Burke LJ, Baniahmad A. Co-repressors 2000. FASB J. 2000 14 : 1876 1888.
10. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 2001 276 : 36865 36868.
11. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001 1 : 34 45.
12. Brinkmann AO, Blok LJ, de Ruiter PE, et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999 69 : 307 313.
13. Culig Z, Klocker H, Bartsch G, et al. Androgen receptors in prostate cancer. Endocr Relat Cancer. 2002 9 : 155 170.
14. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 4 : 236 244.
15. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with and- rogen antagonist. Cancer Res. 1999 59 : 2511 2515.
16. Tindall DJ. Pursuing the androgen pathway on the quest to control prostate cancer. Cancer Biol Ther. 2007 6 805 810.
17. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000 6 : 703 706.
18. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006, 99 : 333 344.
19. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999 81 : 242 251.
20. Veldscholte J, Berrevoets CA, Brinkmann AO, et al. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry. 1992 31 : 2393 2399.
21. Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africa-num and Serenoa repens. Urol Res. 2000 28 : 201 209.
22. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol. 2002 19 : 426 435.
23. Yoshimura Y, Yamaguchi O, Bellamy F, et al. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology. 2003 61 : 474 478.
24. Shenouda NS, Sakla MS, Newton LG, et al. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007 31 : 72 81.
25. Schleich S, Papaioannou M, Baniahmad A, et al. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med. 2006 72 : 807 813.
26. Gast A, Schneikert J, Cato AC. N-terminal sequences of the human androgen receptor in DNA binding and transrepressing functions. J Steroid Biochem Mol Biol. 1998 65 : 117 123.
27. Dotzlaw H, Moehren U, Mink S, et al. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol. 2002 16 : 661 673.
28. Schulz M, Eggert M, Baniahmad A, et al. RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding. J Biol Chem. 2002 277 : 26238 26243.
29. Baniahmad A, Tsai SY, O'Malley BW, et al. Kindred S thyroid hormone receptor is an active and constitutive silencer and a repressor for thyroid hormone and retinoic acid responses. Proc Natl Acad Sci USA. 1992 89 : 10633 10637.
30. Leers J, Steiner C, Renkawitz R, et al. A thyroid hormone receptor-dependent glucocorticoid induction. Mol Endocrinol. 1994 8 : 440 447.
31. Kalkhoven E, Valentine JE, Heery DM, et al. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 1998 17 : 232 243.
32. Dotzlaw H, Papaioannou M, Moehren U, et al. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor. Mol Cell Endocrinol. 2003 213 : 79 85.
33. Protopopov AI, Li J, Winberg G, et al. Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med. 2002 4 : 397 406.
34. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994 54 : 2577 2581.
35. Tanner TM, Verrijdt G, Rombauts W, et al. Anti-androgenic properties of Compound A, an analog of a non-steroidal plant compound. Mol Cell Endocrinol. 2003 201 : 155 164.
36. Moehren U, Papaioannou M, Reeb CA, et al. Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol. 2007 21 : 1039 1048.
37. Negri-Cesi P, Motta M. Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol. 1994 51 : 89 96.
38. Htun H, Holth LT, Walker D, et al. Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell. 1999 10 : 471 486.
39. Welshons WV, Lieberman ME, Gorski J. Nuclear localization of unoccupied oestrogen receptors. Nature. 1984 307 : 747 749. (Pubitemid 14133948)
40. Yamashita S. Intranuclear localization of hormone-occupied and -unoccupied estrogen receptors in the mouse uterus: application of 1 nm immunogold-silver enhancement procedure to ultrathin frozen sections. J Electron Microsc. 1995 44 : 22 9.
41. Chen S, Xu Y, Yuan X, et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA. 2006 103 : 15969 15974. (Pubitemid 44657576)
42. Chuan YC, Pang ST, Cedazo-Minguez A, et al. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem. 2006 281 : 29938 29948.
43. Liao G, Chen LY, Zhang A, et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem. 2003 278 : 5052 5061.
44. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002 9 : 601 610.
45. Zhu P, Baek SH, Bourk EM, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006 124 : 615 629.
46. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004 10 : 33 9.
47. Buzek SW, Sanborn BM. Nuclear androgen receptor dynamics in testicular peritubular and Sertoli cells. J Androl. 1990 11 : 514 520.
48. Mukherjee A, Kirkovsky L, Yao XT, et al. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica. 1996 26 : 117 122.
49. He Y, Yin D, Perera M, et al. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem. 2002 37 : 619 634.
50. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007 87 : 905 931.
51. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008 73 : 233 244.
52. Jenster G, Trapman J, Brinkmann AO. Nuclear import of the human androgen receptor. Biochem J. 1993 293 : 761 768.
53. Masiello D, Cheng S, Bubley GJ, et al. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002 277 : 26321 26326.